Mai Capital Management Eli Lilly & CO Transaction History

Mai Capital Management

$9.87 Billion
Q2 2024

A detailed history of Mai Capital Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Mai Capital Management holds 102,424 shares of LLY stock, worth $93.1 Million. This represents 0.94% of its overall portfolio holdings.

Number of Shares

102,424

Previous 99,145 3.31%

Holding current value

$93.1 Million

Previous $77.1 Million 20.23%

% of portfolio

0.94%

Previous 0.83%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$724.87 - $909.04 $2.38 Million - $2.98 Million	3,279 Added 3.31%	102,424 $92.7 Million
Q1 2024 May 08, 2024	BUY	$592.2 - $792.28 $3.26 Million - $4.37 Million	5,511 Added 5.89%	99,145 $77.1 Million
Q4 2023 Feb 09, 2024	BUY	$525.19 - $619.13 $1.12 Million - $1.32 Million	2,135 Added 2.33%	93,634 $54.6 Million
Q3 2023 Nov 14, 2023	SELL	$434.7 - $599.3 $703,779 - $970,266	-1,619 Reduced 1.74%	91,499 $49.1 Million
Q2 2023 Aug 02, 2023	BUY	$350.74 - $468.98 $33,320 - $44,553	95 Added 0.1%	93,118 $43.7 Million
Q1 2023 May 10, 2023	SELL	$310.63 - $364.82 $2.49 Million - $2.92 Million	-8,003 Reduced 7.92%	93,023 $31.9 Million
Q4 2022 Feb 09, 2023	SELL	$321.55 - $374.67 $3.58 Million - $4.17 Million	-11,135 Reduced 9.93%	101,026 $37 Million
Q3 2022 Nov 15, 2022	SELL	$296.48 - $337.87 $1.63 Million - $1.86 Million	-5,508 Reduced 4.68%	112,161 $36.3 Million
Q2 2022 Jul 19, 2022	BUY	$278.73 - $327.27 $1.17 Million - $1.37 Million	4,191 Added 3.69%	117,669 $38.2 Million
Q1 2022 May 10, 2022	BUY	$234.69 - $291.66 $102,559 - $127,455	437 Added 0.39%	113,478 $32.5 Million
Q4 2021 Feb 11, 2022	BUY	$224.85 - $279.04 $1.15 Million - $1.43 Million	5,132 Added 4.76%	113,041 $31.2 Million
Q3 2021 Nov 12, 2021	BUY	$221.6 - $272.71 $390,016 - $479,969	1,760 Added 1.66%	107,909 $24.9 Million
Q2 2021 Jul 19, 2021	SELL	$180.55 - $233.54 $2.68 Million - $3.46 Million	-14,816 Reduced 12.25%	106,149 $24.4 Million
Q1 2021 May 10, 2021	BUY	$164.32 - $212.72 $564,439 - $730,693	3,435 Added 2.92%	120,965 $22.6 Million
Q4 2020 Feb 16, 2021	BUY	$130.46 - $172.63 $13.9 Million - $18.4 Million	106,512 Added 966.71%	117,530 $19.8 Million
Q3 2020 Oct 26, 2020	SELL	$146.22 - $169.13 $19,008 - $21,986	-130 Reduced 1.17%	11,018 $1.63 Million
Q2 2020 Jul 27, 2020	SELL	$136.42 - $164.18 $26,738 - $32,179	-196 Reduced 1.73%	11,148 $1.83 Million
Q1 2020 Apr 16, 2020	BUY	$119.05 - $147.35 $322,863 - $399,613	2,712 Added 31.42%	11,344 $1.57 Million
Q4 2019 Feb 03, 2020	BUY	$106.92 - $132.43 $425,648 - $527,203	3,981 Added 85.59%	8,632 $1.13 Million
Q3 2019 Oct 29, 2019	BUY	$106.79 - $116.16 $16,338 - $17,772	153 Added 3.4%	4,651 $520,000
Q2 2019 Aug 15, 2019	SELL	$110.79 - $129.32 $123,087 - $143,674	-1,111 Reduced 19.81%	4,498 $498,000
Q1 2019 Apr 29, 2019	SELL	$111.31 - $131.02 $50,423 - $59,352	-453 Reduced 7.47%	5,609 $728,000
Q4 2018 Jan 30, 2019	BUY	$105.9 - $118.64 $38,971 - $43,659	368 Added 6.46%	6,062 $701,000
Q3 2018 Oct 12, 2018	SELL	$85.86 - $107.31 $23,783 - $29,724	-277 Reduced 4.64%	5,694 $611,000
Q2 2018 Aug 16, 2018	SELL	$75.7 - $86.88 $10,295 - $11,815	-136 Reduced 2.23%	5,971 $510,000
Q1 2018 Apr 17, 2018	BUY	$74.21 - $87.6 $6,827 - $8,059	92 Added 1.53%	6,107 $473,000
Q4 2017 Jan 30, 2018	BUY	$81.94 - $87.89 $9,750 - $10,458	119 Added 2.02%	6,015 $508,000
Q3 2017 Oct 12, 2017	SELL	$77.07 - $85.54 $4,547 - $5,046	-59 Reduced 0.99%	5,896 $504,000
Q2 2017 Aug 07, 2017	BUY	N/A	5,955	5,955 $490,000

Others Institutions Holding LLY

# of Institutions

3,887

Shares Held

763M

Call Options Held

6.34M

Put Options Held

7.97M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $864B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.

Account

Mai Capital Management Eli Lilly & CO Transaction History